MedTrace Logo

68Ga-DOTA-hLAG-3 PET Imaging of LAG-3 Expression in Cancers

NCT05346276 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2025-08-08

No results posted yet for this study

Summary

To evaluate the potential usefulness of 68Ga-DOTA-hLAG-3 positron emission tomography/computed tomography (PET/CT) for the evaluation of LAG-3 expression in primary and/or metastatic tumors, compared with histopathological results.

Conditions

  • PET/CT
  • hLAG-3
  • TUMOR

Interventions

DIAGNOSTIC_TEST

68Ga-DOTA-hLAG-3 PET/CT

Each participant receives a single intravenous injection of 68Ga-DOTA-hLAG-3, and undergo PET/CT imaging within the specified time.

Sponsors & Collaborators

  • The First Affiliated Hospital of Xiamen University

    lead OTHER

Principal Investigators

  • Long Sun, PhD · The First Affiliated Hospital of Xiamen University

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-10
Primary Completion
2024-12-13
Completion
2024-12-13

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05346276 on ClinicalTrials.gov